TED Ted Baker Plc

RNS Number:2311S
Tepnel Life Sciences PLC
1 March 2002


               Tepnel Life Sciences PLC - New Board Appointments


Tepnel Life Sciences PLC is pleased to announce the appointment of two new
Directors to its Board. Mr Marvin Miller, a 40-year veteran of the international
pharmaceutical and healthcare industries, becomes a Non-Executive Director,
while Mr Gron Ffoulkes-Davies, the Company's current Financial Controller and
Company Secretary, is appointed Group Finance Director.

Marvin Miller recently retired as President and CEO of US company, Nextran, a
subsidiary of Baxter Healthcare Corporation that is focused on the development
of transgenic animals whose organs are suitable for transplantation. Mr Miller's
vast experience in senior management include roles as Vice President,
Biotechnology Licensing for American Cyanamid (now part of American Home
Products); and executive management positions for companies including Johnson &
Johnson and Hoffmann-LaRoche. Mr Miller was the original Product Manager for
Valium while at Roche.

Mr Miller serves on the boards of several US associations, including the
National Center for Genome Resources and the New York State Biotechnology
Association, and has previously served on the boards of the US Biotechnology
Industry Organisation (BIO) and the American Clinical Laboratory Association.

Mr Ffoulkes-Davies joined Tepnel Life Sciences as Financial Controller and
Company Secretary in November 2001. He trained as a Chartered Accountant with
Arthur Andersen & Co. and has more than ten years subsequent finance experience
with a number of companies, most recently as Group Financial Controller at
Limelight Group plc (now HomeForm Group Limited).

Peter Raymond, Chairman of Tepnel Life Sciences commented, "We are delighted
that both Marvin and Gron are joining the Board of Tepnel. I am particularly
pleased that we will have access to Marvin's deep understanding of the life
science market place as well as his broad range of pharmaceutical contacts both
in the US and internationally. The quality of these appointments highlights
further Tepnel's ambition to become a successful global business based on its
world-leading DNA purification technology."


Notes to editors

Tepnel Life Sciences is a global biotechnology company with a 'tripolar'
strategy focused on providing the biomedical industry with high-throughput
automated DNA purification instruments, manual kits and reagents, as well as 
"downstream" bioanalytical services in areas including pharmacogenomics, drug
analysis, genotyping and genetically modified foods.

The Company was founded in 1992 to exploit DNA technology generated at UMIST
(University of Manchester Institute of Science and Technology) and is listed on
the AIM segment of the London Stock Exchange (AIM: TED).


Further enquiries

Tepnel Life Sciences - 0161 946 2200
Carol Smith, Marketing Communications Manager


HCC De Facto Group - 020 7496 3300
David Dible / Mark Swallow


                      This information is provided by RNS
            The company news service from the London Stock Exchange

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024